As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country is healthier and stronger."

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might run for governor of California.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule. Administration officials did

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

CMS has named 15 additional prescription drugs, including diabetes medication Ozempic, for price negotiations under the Inflation Reduction Act. This marks the second round of negotiations aimed at reducing drug costs for Medicare beneficiaries.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.

Medicare will negotiate drug prices for popular medications like Ozempic and Wegovy, aiming to save billions for taxpayers

BECERRA’S FINAL ACT — During the unveiling of his official portrait on Tuesday, HHS Secretary Xavier Becerra ... of legislation tasking Medicare with negotiating drug prices.